[Antiproteolytic properties of nonsteroid anti-inflammatory agents].
D000614:Aminocaproates / Q000494:pharmacology*; D000632:Aminopyrine / Q000494:pharmacology*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D007611:Aprotinin / Q000494:pharmacology*; D002918:Chymotrypsin / Q000037:antagonists & inhibitors*; D003864:Depression, Chemical; D004487:Edema / Q000139:chemically induced / Q000517:prevention & control; D005557:Formaldehyde / Q000037:antagonists & inhibitors; D066298:In Vitro Techniques; D008528:Mefenamic Acid / Q000494:pharmacology; D051379:Mice; D010653:Phenylbutazone / Q000494:pharmacology*; D011817:Rabbits; D051381:Rats; D012980:Sodium Salicylate / Q000494:pharmacology*; D014357:Trypsin / Q000633:toxicity; D014361:Trypsin Inhibitors / Q000494:pharmacology*; D062367:ortho-Aminobenzoates / Q000494:pharmacology*
D000614:Aminocaproates; D000893:Anti-Inflammatory Agents; D014361:Trypsin Inhibitors; D062367:ortho-Aminobenzoates; D000632:Aminopyrine; D005557:Formaldehyde; D008528:Mefenamic Acid; D007611:Aprotinin; D002918:Chymotrypsin; D014357:Trypsin; D010653:Phenylbutazone; D012980:Sodium Salicylate
Antiproteoliticheskie svoĭstva nesteroidnykh protivovospalitel'nykh sredstv.